Information Provided By: 
Fly News Breaks for December 20, 2016
CLVS, TSRO
Dec 20, 2016 | 07:54 EDT
Baird analyst Michael Ulz said his outlook for TESARO (TSRO) remains unchanged despite the approval of Clovis' (CLVS) ovarian cancer drug. The analyst said the Clovis drug approval was expected and believes its bodes well, as it highlights the FDA's favorable view toward PARP inhibitors. Ulz, who noted TESARO's drug is to be used as an earlier line of therapy, maintained his Outperform rating and $127 price target on TESARO shares.
News For TSRO;CLVS From the Last 2 Days
There are no results for your query TSRO;CLVS
